Refine
Document Type
- Article (46)
Language
- English (46)
Has Fulltext
- yes (46)
Is part of the Bibliography
- no (46)
Keywords
- prostate cancer (10)
- radical prostatectomy (10)
- bladder cancer (4)
- chemotherapy (4)
- external beam radiotherapy (4)
- metastatic prostate cancer (4)
- mortality (4)
- survival (4)
- Adenocarcinoma (3)
- Prostate cancer (3)
- Squamous cell carcinoma (3)
- Variant histology (3)
- primary prostate cancer (3)
- CSM (2)
- Cancer-specific mortality (2)
- Epidemiology and End Results (2)
- FFLU (2)
- HoLEP (2)
- Melanoma (2)
- NCCN (2)
- Penile cancer (2)
- Radical prostatectomy (2)
- SCC (2)
- Surveillance (2)
- Urethral cancer (2)
- biopsy cores (2)
- cancer specific survival (2)
- cancer-specific mortality (2)
- contemporary (2)
- functional outcome (2)
- fusion biopsy (2)
- intermediate risk (2)
- kidney cancer (2)
- localized prostate cancer (2)
- lymph node dissection (2)
- other-cause mortality (2)
- outcomes (2)
- overall survival (2)
- radical cystectomy (2)
- salvage radical prostatectomy (2)
- systematic biopsy (2)
- upgrading (2)
- urological cancer (2)
- very high risk (2)
- ASAP (1)
- Anticoagulation (1)
- BMI (1)
- BPH (1)
- BPO (1)
- Bladder cancer (1)
- Bleeding (1)
- CRPC (1)
- Cancer therapy (1)
- Cancer-specific survival (1)
- Clavien–Dindo classification (1)
- Complications (1)
- Cytoreductive nephrectomy (1)
- Downgrading (1)
- EBRT (1)
- External beam radiotherapy (1)
- Extraprostatic (1)
- Functional outcomes (1)
- Geographical disparities (1)
- Gleason Grade Group (1)
- Gleason Grade group (1)
- Gleason Score (1)
- Gleason grade group (1)
- Gleason score (1)
- HOLEP (1)
- High-risk prostate cancer (1)
- Hispanic–Latino race/ethnicity (1)
- Histology (1)
- Holmium laser enucleation (1)
- IHC (1)
- IPSS (1)
- Incidence rate (1)
- Incidental prostate cancer (1)
- Inferior vena cava thrombus (1)
- Intermediate-risk (1)
- Lee type, functional outcome (1)
- Lee-type (1)
- Long-term continence (1)
- Metastatic renal cell carcinoma (1)
- Mortality (1)
- NIS (1)
- NVBP (1)
- NeuroSAFE (1)
- Non-urothelial (1)
- OR time (1)
- ORP (1)
- Organ-confined (1)
- PAD-test (1)
- PSA (1)
- RARP (1)
- Race (1)
- Region (1)
- Renal vein thrombus (1)
- Robotic-assisted radical prostatectomy (1)
- SEER (1)
- Single positive core biopsy (1)
- Social differences (1)
- Stage at presentation (1)
- TUR-P (1)
- Time trend (1)
- Transfusion (1)
- Transurethral resection of the prostate (1)
- Treatment rates (1)
- Upgrading (1)
- Urinary continence (1)
- Urinary incontinence (1)
- antibiotic treatment (1)
- apex (1)
- blood loss (1)
- bone barrow (1)
- cancer-specific survival (1)
- castration resistance (1)
- catheter (1)
- clinical node positive (1)
- clinical stage (1)
- colon cancer (1)
- complication (1)
- concordance (1)
- cost analysis (1)
- downgrading (1)
- elderly (1)
- epididymitis (1)
- ethnicity (1)
- heart (1)
- high risk (1)
- high-risk (1)
- immunohistochemistry (1)
- incontinence (1)
- kidney (1)
- length of stay (1)
- life table (1)
- life-expectancy (1)
- liver (1)
- local treatment (1)
- low risk (1)
- lung cancer (1)
- lymph node metastases (1)
- membranous urethra (1)
- metastatic urethral cancer (1)
- mid-term urinary continence (1)
- neoadjuvant chemotherapy (1)
- neurovascular bundle preservation (1)
- non-organ confined stage (1)
- open (1)
- other cause mortality (1)
- overtreatment (1)
- pad-test (1)
- perioperative outcome (1)
- post-radiotherapy recurrence (1)
- predictor (1)
- prostate neoplasm (1)
- prostate volume (1)
- race (1)
- race/ethnicity disparities (1)
- radiation (1)
- risk group (1)
- risk score (1)
- robotic-assisted (1)
- secondary cancer (1)
- stage (1)
- stage migration (1)
- suprapubic catheter (1)
- surgical complications (1)
- surgical margin (1)
- transurethral catheter (1)
- upstaging (1)
- urinary incontinence (1)
- very high-risk (1)
Institute
- Medizin (46)
Background: Survival data regarding cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) patients according to the type and extent of tumor-associated vascular thrombus are scarce.
Objective: To test for survival differences in mRCC patients treated with CN according to the type and extent of tumor-associated vascular thrombus.
Design, setting, and participants: Within Surveillance, Epidemiology, and End Results Research Plus (2004–2017), we identified CN mRCC patients with renal vein (pT3a-TT) versus infradiaphragmatic inferior vena cava (IVC; pT3b) versus supradiaphragmatic IVC tumor thrombus/IVC invasion (pT3c).
Outcome measurements and statistical analysis: Overall survival (OS) was addressed in Kaplan-Meier and Cox regression analyses, in addition to 3-mo landmark analyses.
Results and limitations: Of 2170 mRCC patients, 1880 (87%), 204 (9%), and 86 (4%) harbored pT3a-TT, pT3b, and pT3c, respectively. The respective median OS periods were 21, 23, and 12 mo (p < 0.001). In multivariable Cox regression models, pT3c stage, but not pT3b stage, was an independent predictor of higher overall mortality (hazard ratio [HR]: 1.37; 95% confidence interval [CI]: 1.09–1.73; p = 0.007), as well as in 6-mo landmark analyses (HR: 1.36; 95% CI: 1.02–1.80; p = 0.04). In the sensitivity analysis, relying on all pT3a patients, the predictor status of pT3c stage remained unchanged (HR: 1.37; 95% CI: 1.09–1.71; p = 0.007). Limitations have to be addressed regarding the sample size and the retrospective design of the current study.
Conclusions: Although overall mortality is significantly higher in pT3c mRCC patients than in their pT3b and pT3a-TT counterparts, these individuals may still expect 12-mo or better OS after CN versus virtually 2-yr OS in their pT3a and pT3b counterparts.
Patient summary: In this study, we looked at the survival outcomes of metastatic renal cell carcinoma patients who presented with tumor thrombus at cytoreductive nephrectomy. Even though these patients with most advanced tumor thrombus stage demonstrated lower survival rates, the median overall survival was still 1 yr.
Background and Objectives: To test for differences in perioperative outcomes and total hospital costs (THC) in nonmetastatic bladder cancer patients undergoing open (ORC) versus robotic-assisted radical cystectomy (RARC).
Methods: We relied on the National Inpatient Sample database (2016–2019). Statistics consisted of trend analyses, multivariable logistic, Poisson, and linear regression models.
Results: Of 5280 patients, 1876 (36%) versus 3200 (60%) underwent RARC versus ORC. RARC increased from 32% to 41% (estimated annual percentage change [EAPC]: + 8.6%; p = 0.02). Rates of transfusion (8% vs. 16%), intraoperative (2% vs. 3%), wound (6% vs. 10%), and pulmonary (6% vs. 10%) complications were lower in RARC patients (all p < 0.05). Moreover, median length of stay (LOS) was shorter in RARC (6 vs. 7days; p < 0.001). Conversely, median THC (31,486 vs. 27,162$; p < 0.001) were higher in RARC. Multivariable logistic regression-derived odds ratios addressing transfusion (0.49), intraoperative (0.53), wound (0.68), and pulmonary (0.71) complications favored RARC (all p < 0.01). In multivariable Poisson and linear regression models, RARC was associated with shorter LOS (Rate ratio:0.86; p < 0.001), yet higher THC (Coef.:5,859$; p < 0.001). RARC in-hospital mortality was lower (1% vs. 2%; p = 0.04).
Conclusions: RARC complications, LOS, and mortality appear more favorable than ORC, but result in higher THC. The favorable RARC profile contributes to its increasing popularity throughout the United States.
Aim
To compare overall mortality (OM), cancer-specific mortality (CSM), and other cause mortality (OCM) rates between radical prostatectomy (RP) versus radiotherapy (RT) in clinical node-positive (cN1) prostate cancer (PCa).
Materials and Methods
Within Surveillance, Epidemiology, End Results (SEER) (2004–2016), we identified 4685 cN1 PCa patients, of whom 3589 (76.6%) versus 1096 (24.4%) were treated with RP versus RT. After 1:1 propensity score matching (PSM), Kaplan–Meier plots and Cox regression models tested the effect of RP versus RT on OM, while cumulative incidence plots and competing-risks regression (CRR) models addressed CSM and OCM between RP and RT patients. All analyses were repeated after the inverse probability of treatment weighting (IPTW). For CSM and OCM analyses, the propensity score was used as a covariate in the regression model.
Results
Overall, RT patients were older, harbored higher prostate-specific antigen values, higher clinical T and higher Gleason grade groups. PSM resulted in two equally sized groups of 894 RP versus 894 RT patients. After PSM, 5-year OM, CSM, and OCM rates were, respectively, 15.4% versus 25%, 9.3% versus 17%, and 6.1% versus 8% for RP versus RT (all p < 0.001) and yielded respective multivariate hazard ratios (HRs) of 0.63 (0.52–0.78, p < 0.001), 0.66 (0.52–0.86, p < 0.001), 0.71 (0.5–1.0, p = 0.05), all favoring RP. After IPTW, Cox regression models yielded HR of 0.55 (95% confidence interval [CI] = 0.46–0.66) for OM, and CRR yielded HRs of 0.49 (0.34–0.70) and 0.54 (0.36–0.79) for, respectively, CSM and OCM, all favoring RP (all p < 0.001).
Conclusions
RP may hold a CSM advantage over RT in cN1 PCa patients.
The effect of race/ethnicity on cancer-specific mortality after salvage radical prostatectomy
(2022)
Background: To test the effect of race/ethnicity on cancer-specific mortality (CSM) after salvage radical prostatectomy (SRP).
Material and methods: We relied on the Surveillance, Epidemiology and End Results database (SEER, 2004–2016) to identify SRP patients of all race/ethnicity background. Univariate and multivariate Cox regression models addressed CSM according to race/ethnicity.
Results: Of 426 assessable SRP patients, Caucasians accounted for 299 (69.9%) vs. 68 (15.9%) African-Americans vs. 39 (9.1%) Hispanics vs. 20 (4.7%) Asians. At diagnosis, African-Americans (64 years) were younger than Caucasians (66 years), but not younger than Hispanics (66 years) and Asians (67 years). PSA at diagnosis was significantly higher in African-Americans (13.2 ng/ml), Hispanics (13.0 ng/ml), and Asians (12.2 ng/ml) than in Caucasians (7.8 ng/ml, p = 0.01). Moreover, the distribution of African-Americans (10.3%–36.6%) and Hispanics (0%–15.8%) varied according to SEER region. The 10-year CSM was 46.5% in African-Americans vs. 22.4% in Caucasians vs. 15.4% in Hispanics vs. 15.0% in Asians. After multivariate adjustment (for age, clinical T stage, lymph node dissection status), African-American race/ethnicity was an independent predictor of higher CSM (HR: 2.2, p < 0.01), but not Hispanic or Asian race/ethnicity. The independent effect of African-American race/ethnicity did not persist after further adjustment for PSA.
Conclusion: African-Americans treated with SRP are at higher risk of CSM than other racial/ethnic groups and also exhibited the highest baseline PSA. The independent effect of African-American race/ethnicity on higher CSM no longer applies after PSA adjustment since higher PSA represents a distinguishing feature in African-American patients.
Background: The survival benefit of primary external beam radiation therapy (EBRT) has never been formally tested in elderly men who were newly diagnosed with metastatic prostate cancer (mPCa). We hypothesized that elderly patients may not benefit of EBRT to the extent as younger newly diagnosed mPCa patients, due to shorter life expectancy.
Methods: We relied on Surveillance, Epidemiology and End Results (2004–2016) to identify elderly newly diagnosed mPCa patients, aged >75 years. Kaplan–Meier, univariable and multivariable Cox regression models, as well as Competing Risks Regression models tested the effect of EBRT versus no EBRT on overall mortality (OM) and cancer-specific mortality (CSM).
Results: Of 6556 patients, 1105 received EBRT (16.9%). M1b stage was predominant in both EBRT (n = 823; 74.5%) and no EBRT (n = 3908; 71.7%, p = 0.06) groups, followed by M1c (n = 211; 19.1% vs. n = 1042; 19.1%, p = 1) and M1a (n = 29; 2.6% vs. n = 268; 4.9%, p < 0.01). Median overall survival (OS) was 23 months for EBRT and 23 months for no EBRT (hazard ratio [HR]: 0.97, p = 0.6). Similarly, median cancer-specific survival (CSS) was 29 months for EBRT versus 30 months for no EBRT (HR: 1.04, p = 0.4). After additional multivariable adjustment, EBRT was not associated with lower OM or lower CSM in the entire cohort, as well as after stratification for M1b and M1c substages.
Conclusions: In elderly men who were newly diagnosed with mPCa, EBRT does not affect OS or CSS. In consequence, our findings question the added value of local EBRT in elderly newly diagnosed mPCa patients.